Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of scirpenin C in preparation of medicine for treating cerebral arterial thrombosis

A technology for ischemic stroke and trigonidin, applied in the field of biomedicine, can solve the problems of unreported application of trigonidin C, and achieve the effects of reducing cerebral infarct size, inhibiting neurological damage, and increasing SOD content

Active Publication Date: 2021-11-26
GUANGDONG PHARMA UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of trigonin C in the preparation of anti-ischemic stroke drugs has not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of scirpenin C in preparation of medicine for treating cerebral arterial thrombosis
  • Application of scirpenin C in preparation of medicine for treating cerebral arterial thrombosis
  • Application of scirpenin C in preparation of medicine for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 3

[0040] Example 1 Experiment of Inhibitory Effects of Trigonin C on BV2 Cell Hydrogen Peroxide Injury and Hypoxia and Glucose Injury

[0041] 1. Experimental materials

[0042] (1) Experimental cells

[0043] BV2 cell line (mouse microglia) was purchased from Shanghai Cell Resource Center.

[0044] (2) Experimental reagents

[0045]

[0046] (3) Experimental equipment

[0047]

[0048]

[0049] 2. Protective effect of trigonin C on hydrogen peroxide injury model of BV2 cells

[0050] (1) Experimental method

[0051] According to the method of establishing the BV2 cell injury model caused by hydrogen peroxide in the past, and improved it, finally using 400 μmol / L, injury for 24 hours, and the survival rate of BV2 cells as the modeling conditions were 59.4%. explore.

[0052] BV2 cells cultured to passage 5-20 after thawing were seeded in a 96-well plate at a density of 8000 / well, 100 μL per well, and 150 μL of PBS was added to the outermost circle to prevent edge ef...

Embodiment 2 3

[0065] Example 2 The drug effect experiment of trigonin C on cerebral ischemia-reperfusion injury in rats

[0066] 1. Experimental materials

[0067] (1) Experimental animals

[0068] SPF grade SD rats (male, body weight 230±20g), the experimental rats were provided by the Guangdong Medical Experimental Animal Center, license number: SCXK (Guangdong) 2013-0002. They were bred by the Experimental Animal Center of Guangdong Pharmaceutical University.

[0069] (2) Experimental equipment

[0070]

[0071] (3) Experimental reagents

[0072]

[0073]

[0074] 2. Experimental method and experimental results of the efficacy of trigonin C on cerebral ischemia-reperfusion injury in rats

[0075] 1. Grouping and administration of experimental animals

[0076] The male SD rats were randomly divided into 5 groups, namely the sham operation group (Sham), the model group (Model), the high-dose trisensin C group (SC-High), and the trisensin C middle-dose group (SC-Middle) , tri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of scirpenin C in preparation of a medicine for treating cerebral arterial thrombosis. The scirpenin C is co-cultured with hydrogen peroxide damaged BV2 cells and hypoxia-glucose damaged BV2 cells respectively, and results show that the scirpenin C can increase the survival rate of the hydrogen peroxide damaged BV2 cells and the hypoxia-glucose damaged BV2 cells. The anti-cerebral arterial thrombosis performance of the scirpenin C is evaluated by intervening middle cerebral artery occlusion reperfusion model rats with the scirpenin C, and experimental results show that the scirpenin C can inhibit neurological function damage, reduce the cerebral infarction area caused by cerebral arterial thrombosis, reduce the cerebral dampness, significantly relieve cerebral edema and repair the blood brain barrier. The scirpenin C can also obviously reduce cell necrosis, maintain the normal state of cells, reduce the content of LDH, MDA, TNF-alpha and IL-1 beta in serum of the cerebral arterial thrombosis rats and increase the content of SOD.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of trigonin C in the preparation of medicines for treating ischemic stroke. Background technique [0002] Ischemic stroke (Stroke) is a general term for brain tissue necrosis caused by stenosis or occlusion of cerebral blood supply arteries (carotid artery and vertebral artery) and insufficient cerebral blood supply. Ischemic stroke is the leading cause of adult disability and death worldwide, a multifactorial heterogeneous disease associated with genetic and environmental factors. At present, the global treatment methods for ischemic stroke are mainly intravenous thrombolysis and endovascular therapy, but the process of reperfusion after thrombolysis will cause inflammation, oxidative stress and changes in excitatory amino acids, which will further aggravate brain damage. Let the patient's quality of life be weakened in the prognosis, and there is a certain ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/495A61K36/902A61P9/10
CPCA61K31/495A61K36/902A61P9/10
Inventor 王淑美梁生旺贤明华谢媛媛蔡家乐梁嘉茵詹锶楷沈琳林惠婷
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com